INTRODUCTION
Accumulating evidence in adults indicates that HIVinfected individuals have a shorter life expectancy and are at greater risk of HIV-associated non-AIDS (HANA) conditions, such as cardiovascular disease and osteoporosis, despite suppressive antiretroviral therapy (ART), possibly due to accelerated aging. 1, 2 Various biomarkers, including telomere length and DNA methylation (DNAm) age, have been used to measure accelerated biological aging in HIV-infected adults. Shorter telomere length consistent with accelerated aging has been observed in HIV-infected adults compared with HIVuninfected adults, with telomere length inversely associated with immunological recovery with ART as well as HANA outcomes. [3] [4] [5] [6] [7] [8] [9] Similarly, increased DNAm age in different tissues, including blood and brain tissue, has been reported in several studies of HIV-infected adults compared with HIVuninfected adults, including those on suppressive ART. [10] [11] [12] [13] However, there has been very limited application of these biomarkers in studies of HIV-infected children. To the best of our knowledge, there have been only 2 studies of telomere length 14, 15 and no studies of DNAm age in children with HIV. One study found telomere length to be significantly shorter in HIV-infected children (58% on ART) than in HIVexposed uninfected (HEU) and HIV-unexposed uninfected (HUU) children aged 0-5 years (median 3.1 years). 14 The other study of older children (aged 0-19 years, median 13.3 years) did not find any difference in telomere length between HIV-infected children (78% on ART) and HEU or HUU children, although they did find an association between detectable HIV viral load and shorter telomere length in HIV-infected children. 15 It is important to assess accelerated biological aging in pediatric populations. Precursors to HANA conditions, such as metabolic abnormalities and low bone mineral content, are observed in HIV-infected children on ART. 16, 17 Elevated levels of inflammation by cytokines and high-sensitivity Creactive protein and monocyte activation by soluble CD14 are also reported in children with HIV compared with HIVuninfected children. [18] [19] [20] Understanding potential mechanisms for HANA conditions may have important implications for the estimated 2.1 million children currently living with HIV who will experience lifelong exposure to both HIV and its treatments in the absence of a cure. 21 In addition, there are few studies that examine the impact on aging biomarkers of in utero and perinatal exposure to HIV and ART among HEU children.
Here, we assess 2 aging biomarkers-telomere length and DNAm age-and the factors associated with these biomarkers in a cohort of early-treated HIV-infected children in South Africa. We compare these aging biomarkers with HEU and HUU children. We also investigate whether these biomarkers are associated with markers of inflammation.
METHODS

Study Population
Children were selected from an observational cohort study of 553 perinatally HIV-infected children and 300 HIVuninfected controls conducted at 2 sites in Johannesburg, South Africa: Empilweni Services and Research Unit (ESRU) at Rahima Moosa Mother and Child Hospital and the Perinatal HIV Research Unit (PHRU) at Chris Hani Baragwanath Hospital. All HIV-infected children initiated ART before 3 years of age and were former participants in clinical trials at these sites. HIV-uninfected controls were recruited from among eligible siblings or household members of HIVinfected study patients or those attending the study site for routine outpatient health services. Any HIV-uninfected children with known chronic medical conditions were excluded from enrollment. [22] [23] [24] [25] [26] [27] The institutional review boards of Columbia University in New York, NY, USA, and the University of the Witwatersrand in Johannesburg, South Africa approved the study. Children's guardians provided informed consent and children provided assent if they displayed appropriate understanding.
For this analysis, we randomly selected 120 HIVinfected children at the enrollment visit in the cohort study who were initiated on a ritonavir-boosted lopinavir (LPV/r) ART regimen before 24 months of age, had never interrupted treatment, and were suppressed with a viral load ,400 copies per milliliter at the time of blood draw. We also selected 58 HIV-uninfected controls, including 33 HEU children and 25 HUU children, frequency-matched by age at enrollment to the selected HIV-infected children. All selected children had stored blood samples available for analysis. In keeping with standard practice for prevention of mother-to-child transmission at the time, HIV-positive mothers and/or their infants were provided with antiretrovirals; therefore, most HIVinfected and HEU children were exposed to antiretrovirals in utero or in the immediate neonatal period.
Sample Preparation
Venous blood samples were collected and stored at ambient temperature. Within 6 hours of collection, buffy coat and plasma were separated and stored at 280°C by BARC Global Central Laboratory in Johannesburg, South Africa, and shipped on dry ice to Columbia University Medical Center in New York, NY, USA, and stored at 280°C. Buffy coat samples for the measurement of biomarkers of aging were available for both HIV-infected and HIV-uninfected children. Plasma samples for measurement of inflammatory markers were only available for HIV-infected children. Genomic DNA (50 ng/mL) was isolated and quantified with PicoGreen (Life Technologies, Carlsbad, CA) from buffy coat at the Biomarkers Shared Resource at Columbia University Medical Center.
Measurements
At the enrollment visit, demographic information and medical history were obtained by interview with the caregiver. For HIV-infected children, plasma HIV-RNA levels (lower limit of detection 40 copies per milliliter) were measured by the Abbott RealTime HIV-1 Assay (Abbott Laboratories, Abbott Park, IL). CD4 counts and percentage were measured by the TruCount Method (BD Biosciences, Germany).
Biological aging was measured by the biomarkers telomere length and DNAm age in all children. Absolute telomere length in Kb/genome was determined by combination of methods developed by O'Callaghan and Fenech and Cawthon et al using known quantities of synthesized oligonucleotides containing TTAGGG repeats and a single copy gene (albumin) to generate standard curves in a multiplex quantitative polymerase chain reaction (PCR) method. [28] [29] [30] The assay was optimized by measuring both telomere and single copy gene amplifications on the same 384-well plate in a Bio-Rad iQ5 real-time PCR detection system (Bio-Rad, Richmond, CA). Measurements were performed in triplicate and the average was considered the result. This assay was performed at the Biomarkers Shared Resource at Columbia University Medical Center (New York, NY).
DNAm levels were measured using the Infinium HumanMethylation450 BeadChips array (Illumina, San Diego, CA) at the Genomics Shared Resource at Roswell Park Cancer Institute (Buffalo, NY). Samples were randomly distributed across the chips taking into account group, sex, and age to minimize potential batch effects. 31 Preprocessing pipeline procedures, including filtering, background correction, and beta-mixture quantile normalization, were performed with the R/Bioconductor minfi package. 32 Quality control steps were applied to the laboratory pipeline to identify outlying samples and remove non-CpG probes, control probes, single nucleotide polymorphism (SNP)-enriched probes, probes previously demonstrated to potentially cross-hybridize nonspecifically in the genome, 33 unreliable probes with detection P-value $0.05, and sex chromosome probes. DNAm age was measured using the method developed by Horvath et al, which uses 353 CpG dinucleotides to estimate age. 34 In HIV-infected children, plasma markers of systemic inflammation were measured, including cytokines IL-6 (ELI-SA; R&D Systems, Minneapolis, MN) and Tumor necrosis factor (TNF)-alpha (ELISA; R&D Systems, Minneapolis, MN), and high-sensitivity C-reactive protein (CRP) (Cobas Integra 400 Plus; Roche Diagnostics, Indianapolis, IN), an acute phase reactant and marker of general inflammation. In addition, we measured soluble CD14 (ELISA; R&D Systems, Minneapolis, MN), a marker of monocyte activation.
Statistical Analyses
In all analyses, telomere length was natural logtransformed (ln[Kb/genome]) before analysis. The relationship between chronological age and the aging biomarkers was first evaluated to determine the validity of our assay and determine whether it was necessary to adjust for chronological age in subsequent analyses. To adjust for chronological age in our analyses of DNAm age, we used an "age acceleration residual" (residual from regressing DNAm age on chronological age), where positive values greater than 0 indicate accelerated aging and negative values less than 0 indicate decelerated aging. Next, the biomarkers of aging were compared in the 3 groups (HIV-infected, HEU, and HUU). To account for potential confounding by differential cell type distributions in whole blood, analyses of DNAm age comparing HIV-infected and HIV-uninfected groups were adjusted for cell type composition estimated using the method described by Houseman et al. 35 In the HIV-infected children, the following predictors were evaluated for associations with the biomarkers of aging: sex, household smoke exposure (someone in household smokes cigarettes), age at ART initiation, duration on ART, pretreatment CD4 percentage, pretreatment viral load, and current CD4 percentage. Finally, we evaluated whether the biomarkers of aging were related to markers of inflammation in the HIVinfected children, independent of potential confounders.
Continuous variables were descriptively summarized into mean 6 SD and categorical variables into percentages. Unadjusted comparisons of continuous variables were assessed using analysis of variance and t tests, and comparisons of categorical variables were assessed using x 2 or Fisher exact tests. Linear regression was used for adjusted comparisons. Spearman P coefficient was used for correlations. All Pvalues are 2-tailed and P-values ,0.05 were considered statistically significant. Statistical calculations were performed using SAS version 9.4 (Cary, NC).
RESULTS
Study Participants
Demographic characteristics of the 120 HIV-infected children as well as the 33 HEU and 25 HUU children are shown in Table 1 . There were no significant differences in characteristics between the 3 groups. Approximately a third of children in all groups reported exposure to smoke in the household. At the time of measurement, age was 6.4 6 1.4 years and ranged from 4.1 to 9.9 years. The 120 HIV-infected children were all suppressed (viral load ,400 copies per milliliter) with a concurrent CD4 percentage of 33.5 6 6.4 and CD4 count of 1182 6 474 cells/mm 3 . Two children were on an efavirenz-based ART regimen and the remainder on an LPV/r-based ART regimen at the time of measurement. All but one child was on lamivudine and either abacavir (N = 73), zidovudine (N = 20), or stavudine (N = 26). One child was on abacavir and zidovudine. All were previously initiated on an LPV/r-based ART regimen before 24 months of age at an average of 7.8 6 6.1 months.
A 
HIV Infection and Aging Biomarkers
Telomere length and DNAm age were compared with chronological age in the full group of children. Although DNAm age was positively correlated with chronological age (r = 0.57, P , 0.001), telomere length was not (r = 0.007, P = 0.92) (Fig. 1A and B) . There was no significant correlation between chronological age and telomere length even when stratified into HIV-infected (r = 20.09, P = 0.33), HEU (r = 0.02, P = 0.91), or HUU children (r = 0.35, P = 0.09) separately (Fig. 1C) . The correlation between chronological age and DNAm age was positive for HIV-infected (r = 0.58, P , 0.01), HEU (r = 0.56, P , 0.01), and HUU (r = 0.39, P = 0.055) children (Fig. 1D ). Given this, we used an age acceleration residual for our comparisons of DNAm age between groups going forward.
Box-and-whisker plots of telomere length and age acceleration residual by group are shown in Figure 2 . Telomere length (ln[Kb/genome]) was shorter in HIVinfected children compared with HUU children (4.14 6 0.85 vs. 4.53 6 0.79, P = 0.038) and in HEU children compared with HUU children (4.05 6 0.74 vs. 4.53 6 0.79, P = 0.023). There was no significant difference in telomere length between HIV-infected and HEU children (P = 0.58). Findings were similar after adjusting for age (data not shown). Age acceleration residual based on DNAm levels was not different between HIV-infected (20.003 6 2.95), HEU (0.038 6 2.39), and HUU (0.18 6 2.49) children in unadjusted analysis and after adjustment for cell type proportions (data not shown).
Predictors of Aging Biomarkers in HIVInfected Children
Among HIV-infected children, sex, time on ART, and pretreatment viral load were not associated with telomere length or DNAm age acceleration residual (data not shown). As shown in Figure 3A , current CD4 percentage was significantly negatively correlated with age acceleration residual (r=20.36, P , 0.001) in the expected direction (higher CD4 percentage, less age acceleration). Current CD4 percentage was not correlated with telomere length (r = 0.07, P = 0.43). Unexpectedly, we found a weak negative correlation between pretreatment CD4 percentage and telomere length (higher pretreatment CD4 percentage, shorter telomere length) (r = 20.19, P = 0.04) (data not shown). Given the variability in pretreatment CD4 percentage by age, we adjusted the association between pretreatment CD4 percentage and telomere length in a linear regression model for age at the time of the pretreatment CD4 measurement and the association was no longer significant (unadjusted b = 20.015, P = 0.046; adjusted b = 20.014, P = 0.08). There was no correlation between pretreatment CD4 percentage and DNAm age acceleration residual (r = 20.14, P = 0.14) (data not shown).
As shown in Figure 3B , age acceleration residual was higher in the 41 HIV-infected children with reported household smoke exposure compared with the 78 who did not report household smoke exposure (0.712 6 3.63 vs. 20.379 6 2.48, P = 0.05), indicative of more age acceleration in those with exposure to smoke in the household. Telomere length followed the same pattern, with shorter telomere length in children with reported household smoke exposure compared with those without, although not significant (4.01 6 0.86 vs. 4.22 6 0.83, P = 0.21). 
Relationship Between Biological Aging and Markers of Inflammation in HIVInfected Children
Finally, we evaluated the relationship between the aging biomarkers and markers of inflammation in the HIVinfected children (Fig. 4) . We did not observe any associations between the markers of inflammation and either telomere length or DNAm age acceleration residual. There was only a weak negative correlation between soluble CD14 and telomere length (r = 20.14, P = 0.14).
DISCUSSION
We observed no evidence of accelerated biological aging using the biomarker based on DNAm patterns in perinatally HIV-infected children aged 4-9 years who were initiated early on ART and had a suppressed viral load ,400 copies per milliliter at the time of measurement compared with HUU children. By contrast, we observed that absolute telomere length was shorter, generally considered a biomarker of accelerated aging, in both HIV-infected and HEU children compared with HUU children. However, telomere length did not differ between HIV-infected and HEU children.
Our finding of no accelerated aging by DNAm age was in contrast to studies documenting accelerated aging in antiretroviral-naive HIV-infected adults as well as HIVinfected adults with 2 years of ART in comparison with HIV-uninfected adults. 10, 13, 36 It is possible that the negative impact of HIV on DNAm age in these children may occur after a longer duration of infection (ie, greater than a mean of 6.4 years), later in life, or that it was prevented with initiation of ART in perinatally infected children close to the time of primary infection. Given the finding of a strong correlation of DNAm age with chronological age and accelerated DNAm age among those with household smoke exposure, consistent with other reports, 37 the null HIV finding does not seem to be due to inadequacies of the markers we used to assess biological age. If accelerated aging by DNAm age occurs during adolescence and adulthood, long-term follow-up will be necessary to detect this association.
We observed an association between current CD4 percentage and DNAm age, similar to findings from a study of 109 adult men that found a correlation between DNAm age and CD4 + T cells in peripheral blood mononuclear cells (PBMs) (r = 20.23, P = 0.023). 10 That same study found a higher DNAm age in those with a detectable viral load (.35 copies per milliliter) compared with those with a nondetectable viral load, but we were unable to assess this association because we deliberately selected only children who were well suppressed on ART. In the HIV-infected children, accelerated biological aging measured by DNAm age was associated with exposure to smoke in the household, but not with plasma markers of inflammation. The children in this study have been well suppressed on ART for many years and the markers of inflammation that were measured were in the normal range for most children. These findings suggest that adverse environmental events in early life may play an important role in biological aging, as reported in other studies. 38, 39 Our telomere length findings were consistent with a study by Gianesin et al of slightly younger children aged 0-5 years (median 3.1 years) in Spain. 14, 40 Similar to our findings, Gianesin et al reported significantly lower telomere length in HIV-infected children on ART than in HUU infants (T/S ratio 2.46 vs. 2.88, P = 0.0017, personal communication) and a trend of lower telomere length in HEU children than in HUU infants (T/S ratio 2.63 vs. 2.88, P = 0.0537, personal communication), but no significant difference between HIVinfected children on ART and HEU children (P = 0.098).
By contrast, a Canadian study did not find differences in telomere length between HIV-infected, HEU, and HUU children. 15 This may be due to the wider age range in the Canadian study (aged 0-19 years) or a slightly longer duration of ART exposure than children in our study (median 7 vs. 5.7 years in our study). It is possible that longer ART duration may restore telomere length differences, but further follow-up is needed. 14, 15 Two other studies reporting on HEU and HUU children but not HIV-infected children at birth did not find evidence of shorter telomere length in HEU children compared with HUU children 41, 42 ; our study reports on children at a mean age of 6.4 years and in a different setting.
Our findings suggest that telomere length shortening may occur early on in the natural history of the disease (in utero in the case of perinatal HIV infection) and potentially before ART initiation. Supporting this hypothesis are adult studies that show telomere shortening occurring shortly after HIV seroconversion. 7, 43, 44 However, whether this finding is due to in utero HIV infection, in utero HIV exposure, in utero antiretroviral exposure, or other factors is unclear. We were unable to separate HIV infection or exposure from antiretroviral exposure because all children were exposed to antiretrovirals as prevention before initiating treatment. Although we observed an association between pretreatment CD4 percentage and telomere length in unadjusted analyses, this finding did not remain significant after adjustment for age at measurement of pretreatment CD4.
Our study has several limitations. First, we did not measure DNAm levels in specific cell subsets and it is possible that findings may be different; a study in HIVinfected children showed accelerated immune senescence in the CD8 + T-cell subset. 14 Second, quantitative PCR is a practical, but indirect, marker of telomere length. Third, we did not find telomere length to be associated with chronological age in our study, as observed in adults. This null correlation likely reflects the plateau in telomere shortening generally seen in healthy children between age 4 and young adulthood. 45, 46 Fourth, since all HIV-infected children were on ART and virally suppressed, we were unable to assess the impact of no ART or viremia on DNAm age or telomere length. Similarly, we were unable to separate effects of HIV infection or exposure from ART exposure. In addition, we were unable to account for certain unmeasured variables, such as biological father's age, which has been shown to be associated with offspring telomere length or cytomegalovirus infection that is known to be associated with shorter telomeres. 47, 48 Finally, the cross-sectional nature of this study limits our ability to interpret these findings.
In conclusion, a cross-sectional measure of DNAm age was not accelerated in HIV-infected children initiated on ART early compared with HEU and HUU children. Telomere length was shorter in HIV-infected and HEU children compared with HUU children. As the HIV-infected children were initiated and maintained on ART since an early age, the lack of differences between the HIV-infected children and HEU children may be due to viral suppression. Further studies in children are needed to understand whether these findings are sustained longitudinally, and to determine whether the telomere shortening is due to in utero HIV infection, in utero HIV exposure, in utero antiretroviral exposure, or other factors.
